ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for smarter Trade smarter, not harder: Unleash your inner pro with our toolkit and live discussions.
Basilea Pharmaceutica Ag

Basilea Pharmaceutica Ag (0QNA)

46.20
0.00
(0.00%)
Closed January 05 10:30AM

Empower your portfolio: Real-time discussions and actionable trading ideas.

Key stats and details

Current Price
46.20
Bid
45.05
Ask
47.35
Volume
1,765
0.00 Day's Range 0.00
46.20 52 Week Range 46.20
Market Cap
Previous Close
46.20
Open
-
Last Trade
11
@
41.4
(O)
Last Trade Time
Financial Volume
-
VWAP
-
Average Volume (3m)
2,929
Shares Outstanding
12,002,000
Dividend Yield
-
PE Ratio
53.05
Earnings Per Share (EPS)
0.87
Revenue
150.28M
Net Profit
10.45M

About Basilea Pharmaceutica Ag

Sector
Pharmaceutical Preparations
Industry
Pharmaceutical Preparations
Website
Headquarters
Basel, Che
Founded
-
Basilea Pharmaceutica Ag is listed in the Pharmaceutical Preparations sector of the London Stock Exchange with ticker 0QNA. The last closing price for Basilea Pharmaceutica was CHF46.20. Over the last year, Basilea Pharmaceutica shares have traded in a share price range of CHF 46.20 to CHF 46.20.

Basilea Pharmaceutica currently has 12,002,000 shares outstanding. The market capitalization of Basilea Pharmaceutica is CHF554.49 million. Basilea Pharmaceutica has a price to earnings ratio (PE ratio) of 53.05.

0QNA Latest News

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics

Basilea is awarded additional CARB-X funding to develop new drug candidate from a novel class of antibiotics Additional funding awarded following successful drug candidate nominationUSD 7.3...

Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamentenkandidaten einer neuen Antibiotika-Wirkstoffklasse

Basilea erhält zusätzliche CARB-X-Förderung für die Entwicklung eines Medikamentenkandidaten einer neuen Antibiotika-Wirkstoffklasse Zusätzliche finanzielle Förderung aufgrund erfolgreicher...

Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung von Antibiotikum Zevtera® (Ceftobiprol) in den Vereinigten Staaten bekannt

Basilea gibt Vereinbarung mit Innoviva Specialty Therapeutics zur Vermarktung von Antibiotikum Zevtera® (Ceftobiprol) in den Vereinigten Staaten bekannt Ad hoc-Mitteilung gemäss Art. 53 KR...

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States

Basilea announces agreement with Innoviva Specialty Therapeutics for the commercialization of antibiotic Zevtera® (ceftobiprole) in the United States Ad hoc announcement pursuant to Art. 53 LR...

Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus

Starke Cresemba® (Isavuconazol)-Umsätze in Asien-Pazifik und China lösen vierte Meilensteinzahlung für diese Region in diesem Jahr an Basilea aus Allschwil, 10. Oktober 2024 Basilea Pharmaceutica...

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year

Strong Cresemba® (isavuconazole) sales performance in Asia Pacific and China triggers fourth milestone payment for this region to Basilea this year Allschwil, Switzerland, October 10, 2024 Basilea...

Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis

Basilea initiiert klinische Phase-3-Studie mit Antipilzmittel Fosmanogepix bei Candidämie und invasiver Candidiasis Allschwil, 24. September 2024 Basilea Pharmaceutica AG, Allschwil (SIX: BSLN...

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis

Basilea initiates clinical phase 3 study with antifungal fosmanogepix in candidemia and invasive candidiasis Allschwil, Switzerland, September 24, 2024 Basilea Pharmaceutica Ltd, Allschwil (SIX:...

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding

Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding Initial funding of USD 29 million to support development of Basilea’s clinical...

Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung

Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung Bereitstellung eines...

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
10046.246.246.216346.2DE
40046.246.246.2784946.2DE
120046.246.246.2292946.2DE
260046.246.246.2174046.2DE
520046.246.246.2215946.2DE
1560046.246.246.2411146.2DE
2600046.246.246.2390746.2DE

0QNA - Frequently Asked Questions (FAQ)

What is the current Basilea Pharmaceutica share price?
The current share price of Basilea Pharmaceutica is CHF 46.20
How many Basilea Pharmaceutica shares are in issue?
Basilea Pharmaceutica has 12,002,000 shares in issue
What is the market cap of Basilea Pharmaceutica?
The market capitalisation of Basilea Pharmaceutica is CHF 554.49M
What is the 1 year trading range for Basilea Pharmaceutica share price?
Basilea Pharmaceutica has traded in the range of CHF 46.20 to CHF 46.20 during the past year
What is the PE ratio of Basilea Pharmaceutica?
The price to earnings ratio of Basilea Pharmaceutica is 53.05
What is the cash to sales ratio of Basilea Pharmaceutica?
The cash to sales ratio of Basilea Pharmaceutica is 3.69
What is the reporting currency for Basilea Pharmaceutica?
Basilea Pharmaceutica reports financial results in CHF
What is the latest annual turnover for Basilea Pharmaceutica?
The latest annual turnover of Basilea Pharmaceutica is CHF 150.28M
What is the latest annual profit for Basilea Pharmaceutica?
The latest annual profit of Basilea Pharmaceutica is CHF 10.45M
What is the registered address of Basilea Pharmaceutica?
The registered address for Basilea Pharmaceutica is GRENZACHERSTRASSE 487, BASEL, 4058
What is the Basilea Pharmaceutica website address?
The website address for Basilea Pharmaceutica is www.basilea.com
Which industry sector does Basilea Pharmaceutica operate in?
Basilea Pharmaceutica operates in the PHARMACEUTICAL PREPARATIONS sector

Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
TCFTheracryf Plc
0.725p
(38.10%)
7.56M
NMTNeometals Ltd
3.50p
(27.27%)
346.81k
SCHOScholium Group Plc
44.00p
(25.71%)
30.65k
FABFusion Antibodies Plc
10.15p
(24.54%)
3.34M
PYXPyx Resources Limited
3.49p
(22.24%)
8.43k
TM1Technology Minerals Plc
0.125p
(-24.24%)
37.21M
QUIZQuiz Plc
0.70p
(-18.60%)
3.67M
SYMESupply@me Capital Plc
0.003p
(-17.81%)
168.35M
OBDOxford Biodynamics Plc
1.20p
(-14.29%)
827.83k
ZENZenith Energy Ltd.
5.25p
(-13.93%)
5.39M
TRPTower Resources Plc
0.0395p
(5.33%)
539.51M
CPXCap-xx Limited
0.1825p
(1.39%)
494M
NTVONativo Resources Plc
0.0019p
(0.00%)
320.16M
DGIDg Innovate Plc
0.0225p
(-13.46%)
208.21M
ENETEthernity Networks Ltd
0.1125p
(2.27%)
207.56M

Discussion

View Full Feed
Longstrongsilver Longstrongsilver 4 minutes ago
What does this have to do with the stock? I’m confused. Please explain. Starting to think you’re a bashing troll trying to derail the board.
AZRH
Samuel J Samuel J 4 minutes ago
Must be a geezer then... understandable....
AZRH
martyDg martyDg 4 minutes ago
Bark, bark, bark... I bet you're going to look stupid with all the posts you've made here. Nothing is going to happen by the end of January. Watch! You're just going to embarrass yourself by the end of this month.
NWBO
Toronto_Trader Toronto_Trader 4 minutes ago
There’s no pump. Just lots of optimism after a long and devastating 10 years of non-stop dilution and reverse splits by the former CEO. Two Hands is a memory now. Shareholders can rejoice that this is finally on an uptrend.

$TWOH
TWOH
Samuel J Samuel J 4 minutes ago
Come on old man.... can't keep up...


AZRH
Longstrongsilver Longstrongsilver 5 minutes ago
Please keep discussion on the stock. Are you that worried here that you can’t think of anything relevant to say regarding this stock
AZRH
Samuel J Samuel J 5 minutes ago
Drum 🪘 🥁 
AZRH
100lbStriper 100lbStriper 6 minutes ago
ahhh....real music, ty!!!
NLST
Samuel J Samuel J 6 minutes ago
Keep up boy...  keep up...

😜 
AZRH
sentiment_stocks sentiment_stocks 6 minutes ago
I think having the subscription agreement ready for the taking puts them in a stronger negotiating position. If the share price gets to $3 or $5, the dilution to receive $50m is quite minimal, compared to what we, as shareholders, have been used to.

And while accesss to the expertise
NWBO
Longstrongsilver Longstrongsilver 6 minutes ago
So triggered you’re stuck on repeat . Again numbnuts you’re trying to argue with someone who has never bashed the company or our potential here.
AZRH
Samuel J Samuel J 6 minutes ago
Whip whip keep going old horse...  you will get there...

😜 
AZRH
dstock07734 dstock07734 7 minutes ago
So Dr. Vivek Subbiah only helped $NWBO to solve a vendor selection issue. Seriously?

2024
Adaptive Darwinian off-target resistance mechanisms to selective RET inhibition in RET driven cancer
https://www.nature.com/articles/s41698-024-00563-4
V.S. reports resear
NCI NWBO
12x 12x 7 minutes ago
Prof. Grimmer's presentation is still on the AD/PD 2025 website but not the Col24A poster. Did the company withdraw the genetic analysis poster as it did at CTAD24?

Safety data is the primary goal of OLE but everyone's looking for efficacy data. With only 74 patients (assumed based o
JPM
Toronto_Trader Toronto_Trader 7 minutes ago
Any chance of replacing this sticky with one relevant to new management/change of control @Slojab?

Thanks!

$ TWOH
TWOH
fuagf fuagf 7 minutes ago
One of Russia's 'shadow fleet' may have sabotaged power cables in the Baltic Sea. But what is it?

"Russia halts gas exports to Europe via Ukraine, Kyiv hails ‘historic event’
"Volodymyr Zelenskyy suggests Ukraine would give up Russian-occupied territory for NATO membership""
jaramill jaramill 7 minutes ago
$HHSE-NEWS:..Promotional-Partnership.with 'X'-Platform Delivers-Huge-Initial-Response from U.S.-Consumers

News Provided By

Hannover House / MyFlix
January 02, 2025, 18:43 GMT

(Click on link below for EIN Presswire Article)

https://w
HHSE
jaramill jaramill 7 minutes ago
$HHSE: Great Launch of UNHOLY-SONG "Sneak-Peek" Trailer on "X" generates 1 million+ views in first 10 hours!

Wednesday, January 1, 2025

(Click on link below to view Trailer on Blog via YouTube)

https://hannoverhousemovies.blogspot.com/2025/01/great-launc
HHSE
jaramill jaramill 7 minutes ago
$HHSE:..Follow Hannover-House on "X" (Twitter)
Tuesday, December 31, 2024

Link --> https://hannoverhousemovies.blogspot.com/2024/12/follow-hannover-house-on-x-twitter.html HHSE Blog - On X/Twitter

Greetings HHSE Friends & Followers - as part of our promotional
HHSE
Samuel J Samuel J 8 minutes ago
You are doing well keep going boy.  😜 
AZRH
jaramill jaramill 8 minutes ago
$HHSE BLOG: Grateful for the patience and support of our HHSE Longs

Monday, November 18, 2024

https://hannoverhousemovies.blogspot.com/2024/11/grateful-for-patience-and-support-of.html (Click on link to Blog)


Dear HHSE "LONGS" and legitimate sh
HHSE
Longstrongsilver Longstrongsilver 8 minutes ago
Yep that too
AZRH
Samuel J Samuel J 8 minutes ago
I guess you that that too damn well don't you... 

😜 
AZRH